NASDAQ:SLXN Silexion Therapeutics (SLXN) Stock Price, News & Analysis $1.03 -0.47 (-31.00%) Closing price 04:00 PM EasternExtended Trading$1.07 +0.04 (+3.77%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock About Silexion Therapeutics Stock (NASDAQ:SLXN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Silexion Therapeutics alerts:Sign Up Key Stats Today's Range$1.02▼$1.5050-Day Range$1.04▼$4.9952-Week Range$1.02▼$80.00Volume821,851 shsAverage Volume284,556 shsMarket Capitalization$434.70 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. Read More Silexion Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreSLXN MarketRank™: Silexion Therapeutics scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingSilexion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageSilexion Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Silexion Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Silexion Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silexion Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilexion Therapeutics has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Silexion Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.29% of the float of Silexion Therapeutics has been sold short.Short Interest Ratio / Days to CoverSilexion Therapeutics has a short interest ratio ("days to cover") of 0.19, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silexion Therapeutics has recently increased by 62.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSilexion Therapeutics does not currently pay a dividend.Dividend GrowthSilexion Therapeutics does not have a long track record of dividend growth. News and Social Media1.0 / 5News Sentiment-0.35 News SentimentSilexion Therapeutics has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Silexion Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Silexion Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.10% of the stock of Silexion Therapeutics is held by insiders.Percentage Held by Institutions10.95% of the stock of Silexion Therapeutics is held by institutions.Read more about Silexion Therapeutics' insider trading history. Receive SLXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLXN Stock News HeadlinesImmunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)August 10 at 7:25 PM | markets.businessinsider.comSilexion Therapeutics (SLXN) Expected to Announce Quarterly Earnings on TuesdayAugust 10 at 2:10 AM | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.August 11 at 1:00 AM | Banyan Hill Publishing (Ad)Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven CancersAugust 4, 2026 | finance.yahoo.comSilexion Therapeutics Reports Preclinical Data Showing SIL204 Immune-Sensitizing Effects in KRAS-Mutant Cancer CellsAugust 4, 2026 | quiverquant.comQSilexion Therapeutics Announces Board Member ResignationJuly 31, 2026 | tipranks.comSilexion Therapeutics Initiates Phase 2/3 Trial for Pancreatic Cancer Drug CandidateJuly 30, 2026 | finance.yahoo.comSilexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)July 29, 2026 | markets.businessinsider.comSee More Headlines SLXN Stock Analysis - Frequently Asked Questions How have SLXN shares performed this year? Silexion Therapeutics' stock was trading at $19.20 at the beginning of 2026. Since then, SLXN shares have decreased by 94.6% and is now trading at $1.0350. How were Silexion Therapeutics' earnings last quarter? Silexion Therapeutics Corp (NASDAQ:SLXN) issued its quarterly earnings data on Friday, May, 15th. The company reported ($0.85) EPS for the quarter, topping analysts' consensus estimates of ($12.90) by $12.05. When did Silexion Therapeutics' stock split? Silexion Therapeutics shares reverse split before market open on Sunday, July 27th 2025.The 1-15 reverse split was announced on Sunday, July 27th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, July 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Silexion Therapeutics? Shares of SLXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silexion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silexion Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), Baidu (BIDU). Company Calendar Last Earnings5/15/2026Today8/11/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 3 weeks, SLXN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SLXN Previous SymbolNASDAQ:SLXN CIK2022416 Websilexion.com Phone972-2-674-3430Fax212-572-6395EmployeesN/AYear Founded2024Profitability EPS (Trailing Twelve Months)($80.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.91 million Net MarginsN/A Pretax MarginN/A Return on Equity-516.86% Return on Assets-176.68% Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio1.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.33 per share Price / Book0.12Miscellaneous Outstanding Shares420,000Free Float402,000Market Cap$434.70 thousand OptionableN/A Beta-0.25 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:SLXN) was last updated on 8/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLXN Stock Alerts